Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

NCT06837792 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

141

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)

Interventions

DRUG: Experimental treatment arm
DRUG: Control treatment arm

Sponsor

Yonsei University